Literature DB >> 21233488

Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease.

Cameron H Good1, Alexander F Hoffman, Barry J Hoffer, Vladimir I Chefer, Toni S Shippenberg, Cristina M Bäckman, Nils-Göran Larsson, Lars Olson, Sandra Gellhaar, Dagmar Galter, Carl R Lupica.   

Abstract

Parkinson's disease (PD) involves progressive loss of nigrostriatal dopamine (DA) neurons over an extended period of time. Mitochondrial damage may lead to PD, and neurotoxins affecting mitochondria are widely used to produce degeneration of the nigrostriatal circuitry. Deletion of the mitochondrial transcription factor A gene (Tfam) in C57BL6 mouse DA neurons leads to a slowly progressing parkinsonian phenotype in which motor impairment is first observed at ~12 wk of age. L-DOPA treatment improves motor dysfunction in these "MitoPark" mice, but this declines when DA neuron loss is more complete. To investigate early neurobiological events potentially contributing to PD, we compared the neurochemical and electrophysiological properties of the nigrostriatal circuit in behaviorally asymptomatic 6- to 8-wk-old MitoPark mice and age-matched control littermates. Release, but not uptake of DA, was impaired in MitoPark mouse striatal brain slices, and nigral DA neurons lacked characteristic pacemaker activity compared with control mice. Also, hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channel function was reduced in MitoPark DA neurons, although HCN messenger RNA was unchanged. This study demonstrates altered nigrostriatal function that precedes behavioral parkinsonian symptoms in this genetic PD model. A full understanding of these presymptomatic cellular properties may lead to more effective early treatments of PD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233488      PMCID: PMC3058704          DOI: 10.1096/fj.10-173625

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  56 in total

Review 1.  Hyperpolarization-activated cation currents: from molecules to physiological function.

Authors:  Richard B Robinson; Steven A Siegelbaum
Journal:  Annu Rev Physiol       Date:  2002-11-19       Impact factor: 19.318

2.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

Authors:  H Bernheimer; W Birkmayer; O Hornykiewicz; K Jellinger; F Seitelberger
Journal:  J Neurol Sci       Date:  1973-12       Impact factor: 3.181

3.  Intracellular and extracellular electrophysiology of nigral dopaminergic neurons--1. Identification and characterization.

Authors:  A A Grace; B S Bunney
Journal:  Neuroscience       Date:  1983-10       Impact factor: 3.590

4.  Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage.

Authors:  M K Stachowiak; R W Keller; E M Stricker; M J Zigmond
Journal:  J Neurosci       Date:  1987-06       Impact factor: 6.167

Review 5.  Compensatory responses to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animal model of parkinsonism.

Authors:  M J Zigmond; T W Berger; A A Grace; E M Stricker
Journal:  Mol Chem Neuropathol       Date:  1989-06

6.  Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size.

Authors:  E Castañeda; I Q Whishaw; T E Robinson
Journal:  J Neurosci       Date:  1990-06       Impact factor: 6.167

7.  Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain.

Authors:  Y Mizuno; N Sone; T Saitoh
Journal:  J Neurochem       Date:  1987-06       Impact factor: 5.372

Review 8.  Parkinson's disease: mechanisms and models.

Authors:  William Dauer; Serge Przedborski
Journal:  Neuron       Date:  2003-09-11       Impact factor: 17.173

9.  Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions.

Authors:  M J Zigmond; E M Stricker
Journal:  Science       Date:  1973-11-16       Impact factor: 47.728

10.  A voltage-clamp analysis of inward (anomalous) rectification in mouse spinal sensory ganglion neurones.

Authors:  M L Mayer; G L Westbrook
Journal:  J Physiol       Date:  1983-07       Impact factor: 5.182

View more
  56 in total

1.  Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Alicia M Pickrell; Milena Pinto; Aline Hida; Carlos T Moraes
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

2.  Loss of PINK1 causes age-dependent decrease of dopamine release and mitochondrial dysfunction.

Authors:  Lianteng Zhi; Qi Qin; Tanziyah Muqeem; Erin L Seifert; Wencheng Liu; Sushuang Zheng; Chenjian Li; Hui Zhang
Journal:  Neurobiol Aging       Date:  2018-11-02       Impact factor: 4.673

3.  Release parameters during progressive degeneration of dopamine neurons in a mouse model reveal earlier impairment of spontaneous than forced behaviors.

Authors:  Yuan-Hao Chen; Tsung-Hsun Hsieh; Tung-Tai Kuo; Jen-Hsin Kao; Kuo-Hsing Ma; Eagle Yi-Kung Huang; Yu-Ching Chou; Lars Olson; Barry J Hoffer
Journal:  J Neurochem       Date:  2019-05-09       Impact factor: 5.372

Review 4.  Voluntary exercise delays progressive deterioration of markers of metabolism and behavior in a mouse model of Parkinson's disease.

Authors:  Jing-Huei Lai; Kai-Yun Chen; John Chung-Che Wu; Lars Olson; Stefan Brené; Chi-Zong Huang; Yen-Hua Chen; Shuo-Jhen Kang; Kuo-Hsing Ma; Barry J Hoffer; Tsung-Hsun Hsieh; Yung-Hsiao Chiang
Journal:  Brain Res       Date:  2019-06-18       Impact factor: 3.252

5.  Ex Vivo Measurement of Electrically Evoked Dopamine Release in Zebrafish Whole Brain.

Authors:  Mimi Shin; Thomas M Field; Chase S Stucky; Mia N Furgurson; Michael A Johnson
Journal:  ACS Chem Neurosci       Date:  2017-06-28       Impact factor: 4.418

6.  Cypermethrin-induced nigrostriatal dopaminergic neurodegeneration alters the mitochondrial function: a proteomics study.

Authors:  Sonal Agrawal; Ashish Singh; Pratibha Tripathi; Manisha Mishra; Pradhyumna Kumar Singh; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2014-04-24       Impact factor: 5.590

7.  Loss of mitochondrial fission depletes axonal mitochondria in midbrain dopamine neurons.

Authors:  Amandine Berthet; Elyssa B Margolis; Jue Zhang; Ivy Hsieh; Jiasheng Zhang; Thomas S Hnasko; Jawad Ahmad; Robert H Edwards; Hiromi Sesaki; Eric J Huang; Ken Nakamura
Journal:  J Neurosci       Date:  2014-10-22       Impact factor: 6.167

8.  Attenuated response to methamphetamine sensitization and deficits in motor learning and memory after selective deletion of β-catenin in dopamine neurons.

Authors:  Oscar Diaz-Ruiz; Yajun Zhang; Lufei Shan; Nasir Malik; Alexander F Hoffman; Bruce Ladenheim; Jean Lud Cadet; Carl R Lupica; Adriana Tagliaferro; Alicia Brusco; Cristina M Bäckman
Journal:  Learn Mem       Date:  2012-07-20       Impact factor: 2.460

9.  Effect of cholestasis and NeuroAid treatment on the expression of Bax, Bcl-2, Pgc-1α and Tfam genes involved in apoptosis and mitochondrial biogenesis in the striatum of male rats.

Authors:  Mohammad Nasehi; Sepehr Torabinejad; Mehrdad Hashemi; Salar Vaseghi; Mohammad-Reza Zarrindast
Journal:  Metab Brain Dis       Date:  2019-11-26       Impact factor: 3.584

10.  Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products.

Authors:  Michael H Baumann; John S Partilla; Kurt R Lehner; Eric B Thorndike; Alexander F Hoffman; Marion Holy; Richard B Rothman; Steven R Goldberg; Carl R Lupica; Harald H Sitte; Simon D Brandt; Srihari R Tella; Nicholas V Cozzi; Charles W Schindler
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.